ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease-Reference-Cited by-同舟云学术

ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease

Published:2022-06-29 Issue:8 Volume:31 Page:759-771
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Lozupone Madia¹^ORCID,Berardino Giuseppe²,Mollica Anita²,Sardone Rodolfo³,Dibello Vittorio⁴,Zupo Roberta³^ORCID,Lampignano Luisa³,Castellana Fabio³,Bortone Ilaria³^ORCID,Stallone Roberta⁵,Daniele Antonio⁶⁷,Altamura Mario²,Bellomo Antonello²,Solfrizzi Vincenzo⁸,Panza Francesco³^ORCID

Affiliation:

1. Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy

2. Psychiatric Unit, Department of Clinical & Experimental Medicine, University of Foggia, Foggia, Italy

3. Unit of Research Methodology and Data Sciences for Population Health, National Institute of Gastroenterology and Research Hospital IRCCS “S. De Bellis” Castellana Grotte, Bari, Italy

4. Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

5. Neuroscience and Education, Human Resources Excellence in Research, University of Foggia, Foggia, Italy

6. Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy

7. Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy

8. “Cesare Frugoni” Internal and Geriatric Medicine and Memory Unit, University of Bari “Aldo Moro”, Bari, Italy

Funder

This paper was not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2095261

Reference105 articles.

1. Alzheimer’s Disease Facts and Figures. 2021. Last accessed: March 7, 2022. Available from: https://www.alz.org/alzheimers-dementia/facts-figures

2. Cavazzoni P. FDA’s decision to approve new treatment for Alzheimer’s disease. FDA, 2021. Cited March 7, 2022. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decisionapprove-new-treatment-alzheimers-disease

3. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

4. Neuroinflammation in Alzheimer's disease

5. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current trends and updates in the treatment of Alzheimer's disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024

2. Implicative role of cytokines in neuroinflammation mediated AD and associated signaling pathways: Current progress in molecular signaling and therapeutics;Ageing Research Reviews;2023-12

3. Recent advances in anti-inflammatory active components and action mechanisms of natural medicines;Inflammopharmacology;2023-11-10

4. Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds;Medicinal Research Reviews;2023-03-21

5. Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease;Frontiers in Aging Neuroscience;2022-09-07